Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of ligelizumab versus omalizumab/placebo in antihistamine-refractory chronic spontaneous urticaria
MOH_2018-10-17_002436Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ligelizumab and omalizumab in chronic idiopathic urticaria (CIU) (4 arms), sponsored by Novartis. Started Aug 2018; status: active, not recruiting.
02
Drugs
ligelizumabomalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on MOH_2018-10-17_002436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-10-17_002436.